Scottish artist Jacqueline Donachie will screen and discuss her films “Hazel” and “Tomorrow Belongs to Me” Feb. 27 and March 1 as part of UB’s Arts Collaboratory Healthcare Initiative.

Screenings of both films will take place at 12:30 p.m. Feb. 27 and at 6:30 p.m. March 1 in the Screening Room in the Center for the Arts, North Campus. A reception with the artist will follow the screenings. Tickets to the screenings are free and can be reserved online.

Donachie’s work connects patients, researchers and scientists to take an in-depth and very personal look at myotonic dystrophy, a genetic neuromuscular disorder that has affected Donachie’s family. It is characterized by a progressive weakening of the muscles and a reduction of the ability to relax muscles after contraction.

Donachie has worked with a range of scientific and medical professionals in collaborative processes to produce new ideas and artworks that explore myotonic dystrophy and the effects of disability, care and loss.

Her film “Hazel” looks at families affected by myotonic dystrophy. A series of interviews with two sisters affected by the disorder, it reflects on the attitudes and the ongoing effects of myotonic dystrophy on their physical and emotional well-being while also looking at the broader effects of aging.

“Tomorrow Belongs to Me,” made with geneticist Darren Monckton, tells the stories of 11 scientists who played key roles in understanding the underlying molecular mechanisms for myotonic dystrophy and related conditions.

Donachie, who received a PhD from Northumbria University in Glascow, is part of a group of artists who, in the 1990s, helped establish Glasgow as one of the world’s most dynamic contemporary art communities. She has forged an international reputation for a socially engaged art practice, with a particular interest in public space, health care and bio-medical research.

Her doctoral research examined the capacity for artworks to influence research and care in the field of genetics, continuing a long collaborative engagement with biomedical researchers in both Newcastle and Glasgow.